Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pdl1 Positivity Rate Between Triple-Negative and Non-Luminal Her2+ Cases Publisher



Naghizadeh M1 ; Tabriz HM2 ; Kenari AY3 ; Khalili E1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pathology, Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Current Cancer Therapy Reviews Published:2022


Abstract

Background: Triple-negative breast cancer cases with no available targeted therapy and advanced cases of luminal and HER2+ that become resistant to available state-of-the-art treatments are priorities in cancer research. Immune checkpoint blockade, particularly PDL1/PD1 inhibition, is suggested as a potential option for these patients suffering from several other types of cancers, such as melanoma. However, the exact subpopulation of breast cancer patients that overexpress PDL1 is yet to be completely identified. Additionally, reports on the value of PDL1 as a biomarker for the prognosis of cancer and its correlation with clinicopathological features of malignancy are diverse. Methods: In this study, we performed immunohistochemistry on 60 breast cancer, including 22 triple-negative and 38 HER2+ cases, and 20 paired lymph node samples. Results: PDL1 expression was present in 21. 6% (13/60) of breast cancer samples. PDL1 expression is significantly associated with ER/PR negativity and the grade of the tumor. The association between PDL1 positivity and recurrence and the overall survival of patients was not significant. Conclusion: PDL1 expression is similar between triple-negative and non-luminal HER2+ cases, thus some of the advanced non-luminal HER2+ cases might be benefitted from immune checkpoint blockade. © 2022 Bentham Science Publishers.
Related Docs
View other Related Docs
1. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
2. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
3. Tumor Immunology, Clinical Immunology (2022)
4. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
5. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
6. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
7. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
8. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (21)
Hamid Reza Mirzaei (1)
Other Related Docs
9. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
10. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
11. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
12. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)
13. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
14. Immune Checkpoint Inhibitors and Cardiotoxicity: Possible Mechanisms, Manifestations, Diagnosis and Management, Expert Review of Anticancer Therapy (2021)
15. The Role of Myeloid-Derived Suppressor Cells in Lung Cancer and Targeted Immunotherapies, Expert Review of Anticancer Therapy (2022)
16. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
17. Shedding Light on the Side Effects of Immunotherapies Used for Leukemia: An Updated Review of the Literature, Expert Review of Anticancer Therapy (2023)
18. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)
19. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
20. Immune Microenvironment in Different Molecular Subtypes of Ductal Breast Carcinoma, Breast Cancer Research and Treatment (2021)
21. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
22. The Role of Cxc Chemokines and Receptors in Breast Cancer, Clinical and Experimental Medicine (2025)
23. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
24. Introduction on Cancer Immunology and Immunotherapy, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
25. A Narrative Review of Tumor-Associated Macrophages in Lung Cancer: Regulation of Macrophage Polarization and Therapeutic Implications, Translational Lung Cancer Research (2021)
26. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
27. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma, Expert Review of Anticancer Therapy (2021)
28. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
29. Immunotherapy for Breast Cancer Treatment, Iranian Biomedical Journal (2021)
30. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
31. Immune Checkpoints and Graves’ Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review, Journal of Ophthalmic and Vision Research (2024)
32. Expression of Pd1 and Pdl1 As Immune-Checkpoint Inhibitors in Mantle Cell Lymphoma, BMC Cancer (2022)